Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Precision medicine advances in idiopathic pulmonary fibrosis
Τheodoros Karampitsakos, Brenda Juan-Guardela, Argyris Tzouvelekis, et al.
EBioMedicine (2023) Vol. 95, pp. 104766-104766
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Inhalable siRNA Targeting IL-11 Nanoparticles Significantly Inhibit Bleomycin-Induced Pulmonary Fibrosis
Shengting Dong, Huapan Fang, Junjie Zhu, et al.
ACS Nano (2025)
Closed Access | Times Cited: 4
Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis
C.Y. Perrot, Τheodoros Karampitsakos, Jose D. Herazo‐Maya
AJP Cell Physiology (2023) Vol. 325, Iss. 4, pp. C1046-C1057
Open Access | Times Cited: 35
The novel molecular mechanism of pulmonary fibrosis: insight into lipid metabolism from reanalysis of single-cell RNA-seq databases
Xiangguang Shi, Yahui Chen, Mengkun Shi, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Cyclic nucleotide phosphodiesterases as drug targets
Michy P. Kelly, Viacheslav O. Nikolaev, Leila Gobejishvili, et al.
Pharmacological Reviews (2025) Vol. 77, Iss. 3, pp. 100042-100042
Open Access | Times Cited: 1
Applications and challenges of biomedical polymer materials in pulmonary diseases
Dayang Xie, Qiannan Cao, Huapan Fang, et al.
Chinese Chemical Letters (2025), pp. 111032-111032
Closed Access | Times Cited: 1
Mast-cell expressed membrane protein-1 is expressed in classical monocytes and alveolar macrophages in idiopathic pulmonary fibrosis and regulates cell chemotaxis, adhesion, and migration in a TGFβ-dependent manner
C.Y. Perrot, Τheodoros Karampitsakos, Avraham Unterman, et al.
AJP Cell Physiology (2024) Vol. 326, Iss. 3, pp. C964-C977
Open Access | Times Cited: 8
Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
Τheodoros Karampitsakos, Apostolos Galaris, Serafeim Chrysikos, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 16
A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases
M. He, Taoran Yang, Jianguo Zhou, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Forsythoside A regulates pulmonary fibrosis by inhibiting endothelial-to-mesenchymal transition and lung fibroblast proliferation via the PTPRB signaling
Qinqin Zhang, Beibei Zhang, Fan Yang, et al.
Phytomedicine (2024) Vol. 130, pp. 155715-155715
Open Access | Times Cited: 5
Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis
Zezhou Shi, Min Zhou, Jingfang Zhai, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 5
Endothelial H2S-AMPK dysfunction upregulates the angiocrine factor PAI-1 and contributes to lung fibrosis
Xiangqi Chen, Han Wang, Chuan Wu, et al.
Redox Biology (2024) Vol. 70, pp. 103038-103038
Open Access | Times Cited: 4
Role of BAL and Serum Krebs von den Lungen-6 (KL-6) in Patients with Pulmonary Fibrosis
Piera Soccio, Giorgia Moriondo, Miriana d’Alessandro, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 269-269
Open Access | Times Cited: 4
Sinomenine attenuates pulmonary fibrosis by downregulating TGF-β1/Smad3, PI3K/Akt and NF-κB signaling pathways
Fuqiang Yao, Minghao Xu, Lingjun Dong, et al.
BMC Pulmonary Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Therapeutic effects of flavonoids on pulmonary fibrosis: A preclinical meta-analysis
Qi Geng, Lan Yan, Changqi Shi, et al.
Phytomedicine (2024) Vol. 132, pp. 155807-155807
Open Access | Times Cited: 4
An FGF2-Derived Short Peptide Attenuates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting Collagen Deposition and Epithelial–Mesenchymal Transition via the FGFR/MAPK Signaling Pathway
Mengwei Wang, Yuanmeng Sun, Yanzhi Zhao, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 517-517
Open Access
Comparative Analysis of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Epidemiology, Pathophysiology, Clinical Features, Diagnosis and Treatment
César Antonio González-Díaz, Estrella Caballeria, Jacobo Sellar閟 Torres
Deleted Journal (2025) Vol. 3, Iss. 1, pp. 10001-10001
Closed Access
Autologous precision-cut lung slice co-culture models for studying macrophage-driven fibrosis
So-Yi Chang, Wen‐Hsin Chang, David C.H. Yang, et al.
Frontiers in Physiology (2025) Vol. 16
Open Access
Pharmacodynamic Elucidation of Pelargonium zonale (L.) L'Hér. ex Aiton for its Folkloric Claims in Diarrhea and Asthma via in Vitro, in Vivo and in Silico Methods
Rabia Naz, Fatima Saqib, Muhammad Farhaj Latif, et al.
Natural Product Communications (2025) Vol. 20, Iss. 2
Open Access
Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Paolo Spagnolo, Roberto Tonelli, Marco Mura, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-20
Closed Access
Les traitements antifibrosants : où en sommes-nous 10 ans après ?
R. Hindré, Y. Uzunhan
Revue des Maladies Respiratoires (2025)
Closed Access
HMGB1 regulates the activation of dendritic cells and CD4+ T cell responses through the modulation of autophagy in bleomycin-induced pulmonary fibrosis
Xiuhua Liu, Xinghui Song, Guangting Li, et al.
Immunobiology (2025) Vol. 230, Iss. 3, pp. 152906-152906
Open Access
Identification of pyrazole scaffold inhibitors targeting cyclin-dependent kinase 8 for potential use in pulmonary fibrosis
Tony Eight Lin, Kai‐Cheng Hsu, Ching-Hsuan Chou, et al.
Biochemical Pharmacology (2025), pp. 116959-116959
Open Access
Factors influencing long-term outcomes in fibrotic interstitial lung disease (F-ILD) diagnosed through multidisciplinary discussion (MDD): a prospective cohort study
Yu-Wan Liao, Ming-Cheng Liu, Yucheng Wu, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 3
Nets in fibrosis: Bridging innate immunity and tissue remodeling
Xueni Ma, LI Ji-pin, Muyang Li, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112516-112516
Closed Access | Times Cited: 3
Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease
Susumu Sakamoto, Aika Suzuki, Sakae Homma, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top